Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth M Swisher

Showing results (21-30 of 194) with videos related to

Pageof 20
Sort By:
Cancer Genetics and Cytogenetics|May 14, 2008
Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancersKaren M Chisholm, Barbara A Goff, Rochelle Garcia, et al.
American Journal of Obstetrics and Gynecology|May 30, 2006
Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomyJulie D Lamb, Rochelle L Garcia, Barbara A Goff, et al.
Genes, Chromosomes & Cancer|August 14, 2012
E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epitheliumNa Lu Smith, Piri Welcsh, Joshua Z Press, et al.
Molecular Cancer Research : MCR|January 30, 2007
Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiationChristiana DelloRusso, Piri L Welcsh, Weixin Wang, et al.
The Oncologist|October 3, 2019
Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10Yvette Drew, Rebecca S Kristeleit, Ana Oaknin, et al.
Gynecologic Oncology|April 14, 2015
Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlatesJohn B Liao, Yuen Yee Yip, Elizabeth M Swisher, et al.
Cancer Letters|April 13, 2010
Detection of the HE4 protein in urine as a biomarker for ovarian neoplasmsIngegerd Hellstrom, Patrick J Heagerty, Elizabeth M Swisher, et al.
Therapeutic Advances in Medical Oncology|January 31, 2024
The role of aberrant DNA methylation in cancer initiation and clinical impactsFranziska Geissler, Ksenija Nesic, Olga Kondrashova, et al.
Gynecologic Oncology|January 22, 2019
Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefitsSushmita Gordhandas, Barbara M Norquist, Kathryn P Pennington, et al.
Gynecologic Oncology|March 4, 2008
Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancerChirag A Shah, Kimberly H Allison, Rochelle L Garcia, et al.
Pageof 20

Showing results (21-30 of 194) with videos related to

Sort By:
Pageof 20
Cancer Genetics and Cytogenetics|May 14, 2008
Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancersKaren M Chisholm, Barbara A Goff, Rochelle Garcia, et al.
American Journal of Obstetrics and Gynecology|May 30, 2006
Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomyJulie D Lamb, Rochelle L Garcia, Barbara A Goff, et al.
Genes, Chromosomes & Cancer|August 14, 2012
E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epitheliumNa Lu Smith, Piri Welcsh, Joshua Z Press, et al.
Molecular Cancer Research : MCR|January 30, 2007
Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiationChristiana DelloRusso, Piri L Welcsh, Weixin Wang, et al.
The Oncologist|October 3, 2019
Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10Yvette Drew, Rebecca S Kristeleit, Ana Oaknin, et al.
Gynecologic Oncology|April 14, 2015
Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlatesJohn B Liao, Yuen Yee Yip, Elizabeth M Swisher, et al.
Cancer Letters|April 13, 2010
Detection of the HE4 protein in urine as a biomarker for ovarian neoplasmsIngegerd Hellstrom, Patrick J Heagerty, Elizabeth M Swisher, et al.
Therapeutic Advances in Medical Oncology|January 31, 2024
The role of aberrant DNA methylation in cancer initiation and clinical impactsFranziska Geissler, Ksenija Nesic, Olga Kondrashova, et al.
Gynecologic Oncology|January 22, 2019
Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefitsSushmita Gordhandas, Barbara M Norquist, Kathryn P Pennington, et al.
Gynecologic Oncology|March 4, 2008
Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancerChirag A Shah, Kimberly H Allison, Rochelle L Garcia, et al.
Pageof 20